엑셀세라퓨틱스

373110KOSDAQ기초 의약물질 제조업

46.0 / 100

Reference Date: 2026-04-13

Financial Score11.5 / 40

News Sentiment19.5 / 25

Momentum5.0 / 20

Disclosure10.0 / 15

AI Analysis: the high debt ratio poses financial risk, Operating Profit is on a declining trend. Roughly flat over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

Excel Therapeutics focuses on the cell culture media market essential for cell and gene therapy (CGT) development, targeting the rapidly growing cell therapy segment, which is projected to expand from $64 billion in 2024 to $306 billion by 2034. The company is diversifying its business into cultivated meat, cosmetics, artificial blood, and other fields, while advancing domestic media production through continuous R&D.

Number of Employees

65people

Average Salary

66.7M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 33.454.0Point

PBR

3.41Industry Average 2.031.0Point

1.7x industry avg (risky)

ROE

-134.41Industry Average -4.293.5Point

31.3x industry avg (excellent)

Debt Ratio

45.55Industry Average 6.610.0Point

6.9x industry avg (risky)

Trend 2023~20253.0 / 10 points

Revenue Growth Rate

3.0 / 3

Avg ▲36.4% (2-year basis)

Operating Profit Growth Rate

0.0 / 3

Avg ▼11.7% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -157.0% (improving, 3yr)

Detailed News Sentiment

5 totalPositive 4Neutral 0Negative 0Average Sentiment Score 85

Positive
中 시장 공략하는 엑셀세라퓨틱스…35만불 규모 '엑소좀 배지' 수출한....
엑셀세라퓨틱스는 중국 샹야 바이오와 35만 달러 규모의 엑소좀 배지 공급 계약을 체결하며 중국 시장 공략을 본격화했습니다.
Positive
엑셀세라퓨틱스, 노벨상 수상자가 이끄는 中 샹야와 ‘엑소좀 배지’.....
엑셀세라퓨틱스는 노벨상 수상자가 이끄는 중국 샹야 바이오와 엑소좀 배지 공급 계약을 체결하며 중국 엑소좀 연구개발 시장 공략에 나섰습니다.
Positive
엑셀세라퓨틱스, 中 샹야와 '엑소좀 배지' 공급 계약…글로벌 시장 공...
엑셀세라퓨틱스는 중국 샹야 바이오와 엑소좀 배지 공급 계약을 체결하며 글로벌 엑소좀 시장에서 매출 확대 기대감을 높이고 있습니다.

Detailed Momentum

52-week position1.0Point

Near 52w low (4%, downtrend)

Current 1,407Won52-week high 3,64052-week low 1,301

1-month return3.0Point

1m -0.64% (flat)

Volume trend1.0Point

Volume decreasing

Detailed Disclosure

13 totalPositive 0Neutral 13Negative 0

Neutral주식등의대량보유상황보고서(일반)2026-04-01
Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-04-01
Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-04-01
Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-04-01
Neutral[기재정정]주식등의대량보유상황보고서(일반)2026-04-01